{"symbol":"BMY","provider":"yahoo-finance","fetchedAt":"2025-12-23T15:56:57.508Z","asOfDate":"2025-12-23","articles":[{"id":"fe7d0059-6e4d-3def-b51c-bbe5a11f10dc","title":"Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick","url":"https://finance.yahoo.com/news/momentum-investor-1-stock-could-145003209.html","publisher":"Zacks","publishedAt":"2025-12-23T14:50:03.000Z","relatedTickers":[],"mainIdea":"Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick","summary":"Zacks: Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick. Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores."},{"id":"62a09c64-5a85-3fea-b48b-6b60f004c5cf","title":"Office Introverts Want the Boss to Understand Their Plight","url":"https://finance.yahoo.com/m/62a09c64-5a85-3fea-b48b-6b60f004c5cf/office-introverts-want-the.html","publisher":"The Wall Street Journal","publishedAt":"2025-12-23T10:30:00.000Z","relatedTickers":[],"mainIdea":"Office Introverts Want the Boss to Understand Their Plight","summary":"The Wall Street Journal: Office Introverts Want the Boss to Understand Their Plight. The quietest employees have begun speaking up about the ways the office doesnâ€™t work for them. Time for recharge lounges."},{"id":"2dc54035-691e-35fa-af3d-c59a4fb8694a","title":"Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends","url":"https://finance.yahoo.com/news/bet-top-ranked-healthcare-etfs-184300571.html","publisher":"Zacks","publishedAt":"2025-12-22T18:43:00.000Z","relatedTickers":["ABBV","IHE","JNJ","LLY","PFE","VHCIX","VHT","XLV","^GSPC"],"mainIdea":"Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends","summary":"Zacks: Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends. XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership. Related tickers mentioned: ABBV, IHE, JNJ, LLY, PFE, VHCIX, VHT, XLV, ^GSPC."},{"id":"61011386-a8c8-3e29-86b1-2eda14114540","title":"Analyst Report: Bristol-Myers Squibb Company","url":"https://finance.yahoo.com/m/61011386-a8c8-3e29-86b1-2eda14114540/analyst-report%3A-bristol-myers.html","publisher":"Morningstar Research","publishedAt":"2025-12-22T16:35:00.000Z","relatedTickers":[],"mainIdea":"Analyst Report: Bristol-Myers Squibb Company","summary":"Morningstar Research: Analyst Report: Bristol-Myers Squibb Company. Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group."},{"id":"6a874f74-6733-32d9-a28a-ca2b7e5c1e9d","title":"Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up","url":"https://finance.yahoo.com/news/cytokinetics-wins-fda-approval-cardiovascular-142900683.html","publisher":"Zacks","publishedAt":"2025-12-22T14:29:00.000Z","relatedTickers":["CYTK"],"mainIdea":"Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up","summary":"Zacks: Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up. CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology. Related tickers mentioned: CYTK."}]}
